

**1712. *Candida auris*: A Case Series at a Large Tertiary Care Medical System**  
 Preethi Yeturu, MD<sup>1</sup>; Amanda Harrington, PhD<sup>2</sup>; Gail Reid, MD, MSCS<sup>3</sup>; <sup>1</sup>Loyola University Medical Center, Chicago, Illinois; <sup>2</sup>Loyola University and Medical Center, Maywood, Illinois; <sup>3</sup>Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois

**Session:** 165. Mycology  
**Friday, October 4, 2019: 12:15 PM**

**Background.** *Candida Auris* has become one of the most feared pathogens globally in a relatively short period of time and, despite increased awareness, its incidence continues to rise. Recently there has been growing concern regarding drug resistance, difficulty in identification, as well as problems with eradication.

**Methods.** Loyola Medicine includes Loyola University Medical Center, a large tertiary care transplant center, and Gottlieb Memorial Hospital, a community-based medical center. Both hospitals have reported cases of *Candida auris* infection. We reviewed the microbiology laboratory data and clinical information of all positively identified cases over a 17-month period.

**Results.** *Candida auris* was isolated from 14 patients in cultures from blood, urine, wounds, and respiratory secretions. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS; Burkert, Biotyper RUO) was used for identification in all of the cases and susceptibility testing was performed using microbroth dilution (Sensititre, YeastOne) for all isolates. 7/14 isolates (50%) were considered resistant to fluconazole; however, none were multi-drug resistant. All 14 isolates (100%) were considered susceptible to echinocandins. In addition, all patients were critically ill and had multiple comorbidities.

**Conclusion.** *Candida auris* is an emerging global health threat with increasing incidence of infection. Awareness of the pathogen, appropriate contact precautions, and laboratory methods of identification are necessary. Given increasing drug resistance, we recommend susceptibility testing on all isolates.

**Disclosures.** All authors: No reported disclosures.

**1713. Impact of False-Positive Low-Titer Cryptococcal Antigen Testing**

Mahesh Bhatt, MD; Julie A. Ribes, MD, PhD; Vaneet Arora, MD, MPH; Thein Myint, MBBS; University of Kentucky, Lexington, Kentucky

**Session:** 165. Mycology  
**Friday, October 4, 2019: 12:15 PM**

**Background.** At University of Kentucky (UK) HealthCare, the transition from latex agglutination testing (Remel, Lenexa, KS) to IMMY Cryptococcal Antigen Lateral Flow Assay (CrAg LFA) occurred in September 2016. A few months later, it was noticed that several cryptococcal cases were diagnosed with weak positive test results where the diagnosis could not be confirmed by additional testing. The purpose of this study was to analyze the characteristics of these patients, and to assess the interventions they received based on positive results.

**Methods.** This was a retrospective study of the patients with positive CrAg LFA treated at UK HealthCare from November to December 2016. Low antigen titers ( $\leq 1:20$ ) were considered to be false positive if repeat testing with the Remel Cryptococcal Latex assay, IMMY latex and IMMY microwell EIA were negative, cultures and histopathology were negative and there was no clear clinical evidence of infection.


**Results.** During this 2-month period, CrAg LFA was positive in 12 patients. The diagnosis of cryptococcosis could not be confirmed by additional testing in 9 (75%) individuals. Cirrhosis/liver disease was present in 3 (33.3%) patients, 5 (55.6%) underwent lumbar puncture and antifungal therapy was administered in 8 (88.9%) patients (Table 1). CrAg LFA was false positive in 1/2 (50%) HIV, 3/3 (100%) transplant, and 5/7 (71.4%) non-HIV/non-transplant patients (Figure 1). Among the false positives, 4 (44.4%) patients had titer of 1:5, two (22.2%) had 1:20, and the original positive screen was not detected upon titration in 3 (33.3%) other patients. One HIV patient received a complete treatment course for unconfirmed cryptococcal meningitis because an LP could not be performed.

**Conclusion.** False-positive low CrAg LFA titers led to unnecessary tests, antifungal treatments and prolonged hospitalization in some patients. One-third of these individuals had cirrhosis/liver disease. Other institutions also reported false-positive low CrAg LFA titers. As a result, the company staged a recall of the specific lot and corrected the problem in reagent manufacturing. Low-positive titers using CrAg LFA should be interpreted carefully and further testing should be considered as determined by the clinical situation.

**Table 1: Characteristics and Treatment of Nine Patients with False Positive Results**

Characteristics	N(%)
Age	51.7 (25-85) years
Male	8 (88.9%)
Cirrhosis/Liver disease	3 (33.3%)
Underwent Lumbar Puncture	5 (55.6%)
Antifungal Therapy	8 (88.9%)
Antifungal Therapy for > 4 weeks	3 (33.3%)

**Figure 1: False Positive CrAg LFA Results**



**Disclosures.** All authors: No reported disclosures.

**1714. Testing a Novel Clinical Surveillance Case Definition for Invasive Mold Infections**

Karlynn Beer, MS, PhD<sup>1</sup>; Hilary Kelly, MPH<sup>2</sup>; Rebekah Blakney, MS<sup>3</sup>; Taylor Chambers, MPH<sup>4</sup>; Lewis Perry, DrPH, MPH<sup>5</sup>; Sabrina Singleton, MPH, DHSc<sup>6</sup>; Eduard Matkovic, MD<sup>1</sup>; Gillian Hale, MD<sup>1</sup>; Stepy Thomas, MSPH<sup>6</sup>; Nora Oliver, MD, MPH<sup>7</sup>; Alexandra Dretler, MD<sup>8</sup>; Sharon Tsay, MD<sup>9</sup>; Monica R. Farley, MD<sup>7</sup>; Brendan R. Jackson, MD, MPH<sup>1</sup>; CDC, Atlanta, Georgia; <sup>2</sup>Centers for Disease Control and Prevention, Atlanta, Georgia; <sup>3</sup>Georgia Emerging Infections Program, Atlanta, Georgia; <sup>4</sup>VA Health System/Georgia Emerging Infections Program, Atlanta, Georgia; <sup>5</sup>Georgia Emerging Infections Program/Georgia VA Health System, Atlanta, Georgia; <sup>6</sup>Emory University, Georgia Emerging Infections Program, Atlanta, Georgia; <sup>7</sup>Emory University, Atlanta, Georgia; <sup>8</sup>Emory University, Georgia Emerging Infections Program, Atlanta, Georgia

**Session:** 165. Mycology  
**Friday, October 4, 2019: 12:15 PM**


**Background.** Invasive mold infections (IMI) such as aspergillosis and mucormycosis are often fatal among immunosuppressed patients and have caused high-profile outbreaks. Surveillance for IMI is challenging because distinguishing a case from colonization or contamination is complex. The established case definition, Mycoses Study Group (MSG) criteria, lacks sensitivity. Because the need for surveillance remains, we designed a pilot IMI surveillance system within the Georgia Emerging Infections Program. Here, we describe cases identified through this system, using both the MSG criteria and a novel, more sensitive clinical case definition.

**Methods.** To identify potential IMI cases, we captured fungal cultures positive for mold, histopathology specimens with evidence of fungated tissue invasion, and positive galactomannan results within a 60-day window at three large hospitals in Atlanta during March 2017–2018. We excluded dimorphic fungi and hair and nail specimens. Of 194 potential cases, we selected 24 for complete medical chart review. Two physicians classified cases as proven, probable, or non-case according to MSG criteria. Cases that partially met MSG probable criteria and included antifungal treatment were classified as clinical cases; definitions were mutually exclusive (Figure 1).

**Results.** Of 24 potential IMI cases, 16 (66%) met an IMI case definition, including 5 proven, 2 probable and 9 clinical cases. Inter-rater agreement was 92%. Most (5/7) MSG cases involved *Aspergillus* and were more likely to have cancer, a transplant, or other immunosuppression compared with clinical cases (Figure 2 and 3). Clinical cases included conditions not specified in MSG criteria, including burns (1), wounds (1) or eye (4) infections. MSG and clinical cases more often had antifungal treatment (16/16 vs. 1/8) or died (4/16 vs. 0/8) compared with non-cases.

**Conclusion.** In this preliminary analysis of potential IMI cases, most represented true invasive infections, indicating effective exclusion of most colonization. Most of the 16 cases were classified as clinical, however, and would have been missed in a system relying on the MSG criteria alone. Results suggest that a less-specific clinical case definition incorporating antifungal treatment may improve the sensitivity and utility of IMI surveillance.

**Figure 1: Case Classification Algorithm**



<sup>1</sup>For complete MSG proven and probable case definitions, see De Pauw B, Walsh TJ, Donnelly JP, et al. Clin Infect Dis. 2008;46(12):1813-1831